abrdn Healthcare Investors:HQH

    Manage Alerts

    Overview

    As of 12/20/2024

     Share
    Price
    NAVPremium/
    Discount
    Current$16.29$18.47-11.80%
    52 Wk Avg$17.52$19.88-11.85%
    52 Wk High$19.79$21.30-6.63%
    52 Wk Low$15.76$18.31-17.06%
    Regular Distribution TypeManaged Distribution
    Distribution Rate15.22%
    Distribution Amount$0.6200
    Distribution FrequencyQuarterly
    Past performance is no guarantee of future results.

    Basic Information

    Investment Objective

    The Fund's investment objective is to seek long-term capital appreciation by investing primarily in securities of healthcare companies. The Fund will invest primarily in securities of U.S. and foreign companies that are generally believed by the Investment Adviser to have significant potential for above-average long-term growth in revenues and earnings.

    Capital Structure

    As of 12/20/2024

    Total Investment Exposure:$979.178M
    Total Common Assets:$979.178M
    Common Shares Outstanding:53,014,513
    Leverage

    As of 9/29/2023

    Preferred Share Assets:
    Total Debt (USD): $10.380M
    Regulatory Leverage (USD): $10.380M
    Effective Leverage (USD): $10.380M
    Effective Leverage (%): 1.10%
    Annual Expense Ratios

    As of 9/30/2024

      Per Common Share
    Management Fees0.97%
    Other Expenses:0.15%
    Baseline Expense: N/A
    Interest Expense:N/A
    Total: 1.12%
    Fund Management

    Fund Sponsor
    abrdn Inc.

    Portfolio Managers
    Jason C. Akus

    Basics
    Category: Equity-Sector Equity
    Ticker: HQH
    NAV Ticker: XHQHX
    Average Daily Volume (shares): 170,837
    Average Daily Volume (USD): $2.987M
    Inception Date: 4/23/1987
    Inception Share Price: $10.00
    Inception NAV: $0.00
    Tender Offer: No
    Term: No
    Fiscal Year End: September 30
    Third Party Links & Reports

    Distributions

    As of 12/20/2024

    Past performance is no guarantee of future results.
    Distribution History

    Enter declared start and end dates to display distribution history below. Income, Long Gain, Short Gain and ROC breakdowns will only be shown for the past year.

    Declared Date Payable Date Ex Date Distrib Amount Income Long Gain Short Gain ROC

    *Indicates a Special Distribution: A distribution disbursed in addition to the normal distributions paid out by the company.

    Key Information Regarding Distributions
    Avg. Earnings Per Share:
    As of 9/30/2024
    -$0.0051
    Annualized Distribution Rate on NAV:
    As of 12/20/2024
    13.43%
    Total Return on NAV (12 months):
    As of 12/20/2024
    18.78%
    Total % Portfolio Effectively Leveraged:
    As of 12/20/2024
    1.10%

    Pricing Information

    Premium/Discount Information
    Past performance is no guarantee of future results.
    Premium/Discount Information

    As of 12/20/2024

    PeriodAvg Discount
    6 Month-9.46%
    1 Year-11.85%
    3 Year-10.56%
    5 Year-9.37%
    Z-Score

    As of 12/20/2024

    PeriodZStat
    3 Month-2.32
    6 Month-1.54
    1 Year0.02
    Pricing History
    Date NAV Premium / Discount

    Performance

    Calendar Year Total Returns

    As of 11/30/2024
    Category: Morningstar US CEF Sector Equity

    Past 20 Years

    Return YearPriceNAVCategory - PriceCategory - NAV
    YTD19.60%8.83%34.33%19.16%
    20231.32%3.07%4.81%6.23%
    2022-17.35%-6.37%-10.73%-7.15%
    20218.13%2.54%22.39%17.58%
    202024.92%17.57%5.15%5.71%
    201926.81%23.97%26.64%22.38%
    2018-13.12%-7.75%-12.35%-9.96%
    201716.01%15.87%18.18%12.88%
    2016-22.40%-19.93%17.45%14.67%
    20155.10%8.56%-15.98%-12.75%
    201428.33%33.12%5.16%4.65%
    201368.08%53.67%16.34%17.44%
    201233.40%27.05%12.53%11.75%
    201115.39%11.19%  
    201019.19%10.06%  
    200912.30%12.15%  
    2008-26.12%-21.94%  
    20079.23%16.80%  
    2006-0.14%2.08%  
    20057.06%8.11%  
    200411.81%7.42%  
    Past performance is no guarantee of future results.
    Annualized Total Returns

    Returns for periods less than one year are cumulative rather than annualized

    As of 11/30/2024
    Category: Morningstar US CEF Sector Equity

    Past performance is no guarantee of future results.

    Portfolio Characteristics

    Portfolio Characteristics
    Number of Holdings:
    As of 11/30/2024
    135
    Annual Portfolio Turnover:
    As of 9/30/2024
    44.00%
    Asset Allocation

    As of 11/30/2024

    Top Sectors

    As of 11/30/2024

    Sector%Portfolio
    Healthcare89.50%
    Defensive (Super Sector)89.50%
    Corporate (Super Sector)5.90%
    Preferred Stock5.68%
    Cash Equivalents (Super Sector)3.66%
    Cash Equivalents3.66%
    Convertible0.22%
    Top Holdings

    As of 11/30/2024

    HoldingValue% Portfolio
    Gilead Sciences Inc$72.33M6.99%
    Amgen Inc$64.64M6.25%
    Vertex Pharmaceuticals Inc$54.99M5.32%
    Regeneron Pharmaceuticals Inc$51.53M4.98%
    AstraZeneca PLC ADR$32.39M3.13%
    Biogen Inc$29.89M2.89%
    Sarepta Therapeutics Inc$27.83M2.69%
    Eli Lilly and Co$25.33M2.45%
    Alnylam Pharmaceuticals Inc$25.18M2.43%
    BioNTech SE ADR$25.03M2.42%
    Credit Quality

    As of 11/30/2024

    Country Allocation

    As of 11/30/2024

    Country% Portfolio
    United States - Equity79.92%
    United Kingdom - Equity3.13%
    Germany - Equity2.42%
    Denmark - Equity1.56%
    Netherlands - Equity0.87%
    Canada - Equity0.57%
    Switzerland - Equity0.55%
    Israel - Equity0.47%
    Ireland - Equity0.01%
    China - Equity0.00%

    Closed-end fund historical distribution sources have included net investment income, realized gains, and return of capital. For more detailed information on the distributions of a specific fund, please visit the sponsor's website.

    NOTES:

    Distribution type sourced from Morningstar. In general, managed distributions may be sourced from net investment income, realized gains and return of capital. CEFConnect.com does not undertake to disclose specific information about closed-end fund distribution sources. For specific information about a fund's distribution sources, visit the fund sponsor's website.

    The following information applies to closed-end funds in general: Fund shares are not guaranteed or endorsed by any bank or other insured depository institution, and are not federally insured by the Federal Deposit Insurance Corporation. Shares of closed-end funds are subject to investment risks, including the possible loss of principal invested. There can be no assurance that fund objectives will be achieved. Closed-end funds frequently trade at a discount to their net asset value. NAV returns are net of fund expenses, and assume reinvestment of distributions.

    E-2949862P-E0623W